Hub Services Platforms: ConnectiveRx vs AssistRx vs CareMetx vs EVERSANA | Rx Almanac
Head-to-head comparison of the four leading independent (non-wholesaler-owned) hub services platforms for specialty drug patient support. Represents the core vendor selection decision for manufactu...
Overview
Hub services have evolved from “nice to have” into table stakes for any specialty drug launch. The global hub services market was valued at roughly $5.2 billion in 2024 and is projected to reach $13.7 billion by 2033, growing at an 11.2% CAGR. North America accounts for approximately 48% of that revenue base.
These four vendors share a common service core: benefit verification (BV), prior authorization (PA) support, copay and patient assistance program (PAP) administration, and specialty pharmacy triage. Where they diverge sharply is in scale, technology philosophy, specialty pharmacy ownership, PE backing, and the types of launches they are best equipped to serve.
Competitor Profiles
ConnectiveRx
Headquartered in Whippany, NJ. Largest independent hub platform by program volume. Recapitalized in 2020 under Genstar Capital as majority owner, with Harvest Partners SCF and Blackstone Tactical Opportunities as minority investors. Scale: 450+ supported brands, 600+ programs, 170+ pharma manufacturing partners, and 90 million patients supported annually. Operates Careform Pharmacy (non-commercial pharmacy) for in-workflow access.
AssistRx
Founded 2009, based in Orlando, FL. “Tech + talent” philosophy — software and human expertise deeply integrated. Nine of the top 10 largest biotech companies are clients, serving 40+ life sciences organizations. Welsh, Carson, Anderson & Stowe (WCAS) acquired AssistRx in February 2024 for ~$600 million. Acquired AllazoHealth assets in April 2025, adding AI-driven personalized patient engagement.
CareMetx
Founded 2011, headquartered in Bethesda, MD. Tech-forward mid-tier: strong API-first architecture with 2 million patients served annually and 33% improvement in time-to-therapy. General Atlantic invested as majority owner in January 2021 while Vistria Group maintained significant position. Serves 80+ brands. Acquired PX Technology in April 2024 (provider network connectivity). OutcomeRx business unit for value-based contracting.
EVERSANA
Full-spectrum commercialization company — hub services is one module within a much broader platform. Backed by JLL Partners and Water Street Healthcare Partners. Over 6,000 employees, supports 650+ life science organizations. EVERSANA COMPLETE Commercialization model adopted by 20+ companies for 40+ complex therapy launches. Operates an owned specialty pharmacy with direct-to-patient dispensing.
Head-to-Head Comparison
Service Breadth
| Service | ConnectiveRx | AssistRx | CareMetx | EVERSANA |
|---|---|---|---|---|
| Benefit Verification (eBV) | Real-time | Real-time (ABV, <seconds) | Real-time | ACTICS eAccess (seconds) |
| Prior Authorization (ePA) | 150,000+ ePAs/yr | APA (real-time, minutes) | AI-assisted | ACTICS eAccess (>90% success) |
| Copay Program Administration | Full suite + Copay ePA | Full suite + eCopay | Full suite | Full suite |
| Patient Assistance Programs | Yes | Yes (automated re-enrollment) | Yes | Yes |
| Nursing / Clinical Support | Regional case managers | ACE virtual nurse visits | Yes | In-home nursing + clinical pharmacists |
| Adherence / Outreach | Yes | AllazoHealth AI (7.3% decrease in discontinuation) | Behavioral science-based | AI-driven + ACTICS predictive analytics |
| Non-commercial / Bridge Pharmacy | Careform NCP | Non-commercial pharmacy | Partnered | Owned specialty pharmacy |
| Direct-to-Patient Dispensing | Via NCP | Piloted | Partnered | Full DTP dispensing |
| Value-based / Outcomes Contracts | Limited | Limited | OutcomeRx division | Lyfegen integration |
| Full Commercialization | No | No | No | EVERSANA COMPLETE |
Technology Platform
| Capability | ConnectiveRx | AssistRx | CareMetx | EVERSANA |
|---|---|---|---|---|
| Core platform | Proprietary hub + Copay ePA | iAssist / CoAssist | CareMetx Connect | ACTICS by EVERSANA |
| eBV speed | Real-time | <seconds via ABV | Near real-time | Seconds (>90% covered lives) |
| EHR integration | Yes | Yes (Allscripts, CoAssist point-of-prescribing) | Yes (PM-integrated) | Yes |
| AI / predictive analytics | Limited | AllazoHealth AI (acquired 2025) | AI for AR re-verifications | ACTICS ML (up to 50% adherence improvement) |
| HCP-facing portal | ePEF | iAssist (100K+ registered HCP users) | EHR-integrated | Yes |
| Pharmacy connectivity | 77,000+ pharmacies | 77,000+ Surescripts + 140K+ specialty | Partnered SP network | Owned SP + broad network |
Technology edge: AssistRx’s iAssist is the strongest HCP-facing tool (100,000+ registered HCP users, 3.7 million patient touchpoints annually — free to providers). EVERSANA’s ACTICS eAccess is the most ambitious eBV/ePA claim (1,400+ payers, 90%+ of U.S. covered lives). CareMetx’s Connect is the most API-forward for manufacturers wanting hub data in their existing commercial tech stack.
Specialty Pharmacy Integration
| Dimension | ConnectiveRx | AssistRx | CareMetx | EVERSANA |
|---|---|---|---|---|
| Owned specialty pharmacy | Yes — Careform NCP (non-commercial) | Yes — non-commercial pharmacy | No (partnered) | Yes — full commercial SP |
| DTP dispensing | Via Careform NCP | Piloted | Via SP partners | Full DTP — all 50 states |
| Cold-chain capability | Via NCP | Via SP partners | Via SP partners | Owned cold-chain |
Pharmacy ownership matters most for: (1) gene/cell therapy launches requiring controlled dispensing and concierge logistics — EVERSANA wins; (2) bridge therapy/PAP programs — ConnectiveRx’s Careform and AssistRx’s NCP accelerate time-to-first-dose; (3) rare disease limited distribution where hub-to-pharmacy handoff speed is critical.
PE Ownership and Strategic Direction
| ConnectiveRx | AssistRx | CareMetx | EVERSANA | |
|---|---|---|---|---|
| Primary owner | Genstar Capital | WCAS | General Atlantic | JLL Partners + Water Street |
| Ownership event | Recapitalized 2020 | Acquired 2024 (~$600M) | GA majority from Jan 2021 | Refinanced $1.058B debt (2024) |
| Strategic focus | Patient access + adherence; single-partner hub | Tech-enabled therapy initiation; EHR-connected digital hub | Digital hub, API-first; value-based contracts (OutcomeRx) | Full-stack commercialization; EVERSANA COMPLETE |
| Recent moves | PDR/provider network expansion to 1.2M HCPs | AllazoHealth AI acquisition (Apr 2025); headcount doubling | PX Technology acquisition (Apr 2024); Syneos Health partnership (Oct 2025) | Waltz Health merger; $1.75B continuation fund; Memphis DC expansion |
Strategic read: WCAS’s ~$600M AssistRx acquisition signals a bet on tech-enabled access as independent growth platform. General Atlantic’s CareMetx backing positions it for further consolidation or IPO. EVERSANA’s continuation fund and aggressive M&A suggest building toward IPO or strategic sale. ConnectiveRx under Genstar is the most mature PE story and may be approaching a sale process.
Time-to-Therapy Metrics
| Vendor | Published Metric | Context |
|---|---|---|
| ConnectiveRx | 92% of case manager referrals reach “ready to start therapy” | 150,000+ ePAs annually |
| AssistRx | Prescription-to-therapy time: 12.2 days to 3.7 days (~70% reduction) with CoAssist | Most precisely cited metric |
| AssistRx | AllazoHealth AI: 7.3% decrease in discontinuation; 18.8% increase in days on therapy | 25% lower program operating spend |
| CareMetx | 33% faster time-to-therapy vs. baseline | Methodology not disclosed |
| EVERSANA | 95% patient satisfaction, 94% adherence rate (specialty pharmacy) | Subset of hub enrollees |
| EVERSANA | ACTICS eAccess: >90% eBV accuracy vs. 60% industry average | Industry benchmarked |
Caveats: All vendors self-publish outcomes data. None independently audited. AssistRx’s 12.2 to 3.7 day figure is the most operationally specific. EVERSANA’s 94% adherence applies specifically to specialty pharmacy patients. CareMetx’s 33% claim is the vaguest.
Manufacturer Client Base
| ConnectiveRx | AssistRx | CareMetx | EVERSANA | |
|---|---|---|---|---|
| Pharma partners | 170+ manufacturers | 40+ life sciences companies | 80+ brands | 650+ organizations (all services) |
| Programs managed | 600+ | Not disclosed | Not disclosed | Not disclosed |
| Patients annually | 90M | 3.7M touchpoints via iAssist | 2M | Not disclosed |
| Client tier | Mix large pharma + mid-size biotech | Skewed to large biotech (9/10 top biotechs) | Mix, specialty brands | Emerging/mid-size biotech (COMPLETE) + large pharma point services |
Pricing Structure
| Model | Description | Best Match |
|---|---|---|
| FTE-based | Monthly fee per dedicated FTE | Larger brands with predictable volume |
| Per-transaction | Fee per BV, PA, referral, call | Smaller programs; common across all four |
| Per-patient | Fee per enrolled/active patient | Mid-tier brands |
| Outcomes-based | Fee tied to adherence, time-to-therapy | CareMetx OutcomeRx, EVERSANA Lyfegen |
| Deferred billing | Fees deferred until commercial milestones | EVERSANA COMPLETE: 30-50% fee deferral |
Use Case Recommendations
Choose ConnectiveRx when:
- Scale and program breadth are paramount. 600+ programs, 170+ pharma partners — most operational depth among independent peers.
- You need a true single-partner solution with hub, copay, NCP bridge pharmacy, and adherence messaging under one roof.
- Buy-and-bill or NCP complexity — Careform NCP integration is purpose-built.
- Physician engagement at scale — 1.2 million engaged HCP network.
Weakness: Technology self-disclosure is thinner than peers. Platform less differentiated on AI/analytics versus CareMetx or EVERSANA. Large-scale programs may experience the “big hub” problem with less customization flexibility.
Choose AssistRx when:
- Speed to therapy from point of prescription is top priority. CoAssist/iAssist delivers documented 70%+ reduction in prescription-to-therapy time. No comparable point-of-prescribing tool with 100K+ registered HCP users.
- Your prescriber base is tech-forward and you want the hub invisible to the HCP.
- You are a biotech company — 9/10 top biotech claim reflects genuine enterprise relationships.
- AI-driven adherence optimization is a priority — AllazoHealth adds 7.3% decrease in discontinuation, 18.8% more days on therapy, 25% lower operating cost.
Weakness: No full commercial specialty pharmacy for DTP. Smaller absolute client base (40+ vs. ConnectiveRx’s 170+). WCAS acquisition is recent; integration still establishing.
Choose CareMetx when:
- API integration with your commercial tech stack is a hard requirement. Native Salesforce integration and open API architecture.
- Evolving program portfolio — modular configurability for adding brands, changing payer rules mid-launch.
- Value-based contracting is on the horizon. OutcomeRx is the most developed outcomes-contracting capability.
- Transitioning from another vendor. 35+ successful program transitions marketed.
Weakness: Serves 80+ brands (fewer than ConnectiveRx). Lacks owned specialty pharmacy. 33% time-to-therapy claim least substantiated.
Choose EVERSANA when:
- Emerging or mid-size biotech without internal commercial infrastructure. EVERSANA COMPLETE provides outsourced sales force, market access, marketing, distribution, hub, and specialty pharmacy in one contract with deferred billing.
- Rare disease or gene/cell therapy requiring cold-chain logistics, concierge management, limited distribution, outcomes-based coverage.
- Direct-to-patient dispensing — only one of the four with full DTP infrastructure (all 50 states, cold-chain, robotics).
- Global expansion — operates U.S. and EU markets plus China distribution partnership.
Weakness: Most expensive and complex. For large pharma with established commercial infrastructure needing just a hub, the full EVERSANA stack is overkill. Hub-specific outcomes data hard to isolate from integrated model. $1.058B debt load worth monitoring.
Verdict
ConnectiveRx is the safest choice for proven, high-volume operational excellence in mature therapeutic areas — the “institutional” hub. Its scale advantage (600+ programs, 90M patients) is real and matters in fast-enrollment, high-PA-burden launches.
AssistRx is the strongest choice when technology-driven speed at the point of prescription is the top commercial objective. iAssist is the clearest competitive differentiator, and WCAS capital plus AllazoHealth position it well for AI-enhanced programs. The documented 70%+ time-to-therapy reduction is the most operationally specific outcome claim.
CareMetx is the right call when the commercial team is technically sophisticated and wants rich hub data flowing into its own systems — or when outcomes-based contracting (OutcomeRx) is part of the strategy. Also the clearest choice for vendor transitions.
EVERSANA is uniquely suited for emerging biotech with no commercial infrastructure needing an integrated partner — or any manufacturer launching rare disease/gene therapy requiring owned pharmacy, cold-chain, and concierge management. For large pharma running a standalone hub RFP, the other three are more attractive.
Practical note: Manufacturers increasingly run hybrid models — using a technology provider like AssistRx or CareMetx for the digital access layer while relying on the hub for case management. All four now market point-solution and API-only configurations, meaning the binary “pick one hub” decision is less accurate than five years ago.
Related Wiki Pages
Vendor Profiles
Category Pages
Concept Pages
- Hub Services Overview
- Patient Access Journey
- PE Consolidation in Pharma Services
- Prior Authorization
Related Comparisons
- ConnectiveRx vs EVERSANA — Deeper two-way comparison
- AI Prior Authorization Vendors — AI PA automation layer that augments hub services
Frequently Asked Questions
What are the leading independent hub services platforms?
The four leading independent (non-wholesaler-owned) hub services platforms are ConnectiveRx (largest by program volume with 600+ programs and 170+ pharma partners), AssistRx (tech-forward with iAssist platform and 100K+ registered HCP users), CareMetx (API-first architecture with OutcomeRx for value-based contracting), and EVERSANA (full-stack commercialization with owned specialty pharmacy). Each serves different buyer profiles based on scale, technology needs, and commercial infrastructure requirements.
How do ConnectiveRx, AssistRx, CareMetx, and EVERSANA compare?
ConnectiveRx is the institutional choice for proven high-volume operational excellence with 90M patients supported annually. AssistRx offers the strongest technology-driven speed with a documented 70%+ reduction in prescription-to-therapy time via CoAssist. CareMetx is best for API integration and value-based contracting through its OutcomeRx division. EVERSANA is uniquely suited for emerging biotechs needing an integrated partner from field force through dispensing. All four now offer modular configurations beyond the traditional full-hub model.
Which hub services vendor is best for biotech companies?
For emerging biotechs without internal commercial infrastructure, EVERSANA's COMPLETE Commercialization model provides outsourced sales force, market access, hub, and specialty pharmacy in one contract with 30-50% deferred billing. For mid-size biotechs with some commercial presence wanting focused hub and copay services, ConnectiveRx's dedicated FTE model at $2-8M annually is the sweet spot. AssistRx is strongest for tech-forward biotechs prioritizing speed from prescription to therapy, with 9 of the top 10 biotech companies as clients.
How much does the hub services market cost?
The global hub services market was valued at roughly $5.2 billion in 2024 and is projected to reach $13.7 billion by 2033, growing at an 11.2% CAGR. North America accounts for approximately 48% of that revenue. Pricing models include FTE-based (monthly fee per dedicated agent), per-transaction (fee per BV, PA, or call), per-patient (fee per enrolled patient), and outcomes-based models tied to adherence or time-to-therapy metrics.